Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 1,004.27 million.
According to PWC, “2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels.” Below is a.
The Small Molecule API Market is poised to display a solid 5% Compound Annual Growth Rate (CAGR) from 2022 to 2032, ultimately reaching a substantial valuation of US$ 216.97 billion by the end of the forecast period. According to the report, while in-house manufacturing currently holds a dominant position in the mar.
According to a recent market survey conducted by Future Market Insights (FMI), the global Small Molecule-Drug Conjugates Market will be valued at US$ 1.18 billion in 2026 and is expected to reach US$ 3.65 billion by 2033.The increased use of personalised medicines is propelling market growth. Small molecule drug con.